Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH; DoCaCel Study Group.

Ann Oncol. 2012 Nov;23(11):2896-902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11.

PMID:
22689176
2.

Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition.

van Cruijsen H, Oosterhoff D, Lindenberg JJ, Lougheed SM, Fehres C, Weijers K, van Boerdonk R, Giaccone G, Scheper RJ, Hoekman K, de Gruijl TD.

Immunotherapy. 2011 Sep;3(9):1051-61. doi: 10.2217/imt.11.107.

PMID:
21913828
3.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

4.

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G.

Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12.

PMID:
20061136
5.

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE.

J Clin Oncol. 2009 Dec 20;27(36):6152-9. doi: 10.1200/JCO.2009.22.2273. Epub 2009 Nov 9.

PMID:
19901116
6.

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

van Cruijsen H, van der Veldt A, Hoekman K.

Front Biosci (Landmark Ed). 2009 Jan 1;14:2248-68. Review.

PMID:
19273199
7.

Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.

Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, Boven E, van Hinsbergh VW, Broxterman HJ.

Angiogenesis. 2009;12(1):69-79. doi: 10.1007/s10456-009-9133-9. Epub 2009 Feb 11.

PMID:
19212818
8.

Proteomics of the TRAP-induced platelet releasate.

Piersma SR, Broxterman HJ, Kapci M, de Haas RR, Hoekman K, Verheul HM, Jiménez CR.

J Proteomics. 2009 Feb 15;72(1):91-109. doi: 10.1016/j.jprot.2008.10.009. Epub 2008 Nov 8.

PMID:
19049909
9.

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival.

van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, Hoekman K, de Gruijl TD.

Clin Cancer Res. 2008 Sep 15;14(18):5884-92. doi: 10.1158/1078-0432.CCR-08-0656.

10.

Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.

van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G, de Gruijl TD.

Clin Dev Immunol. 2007;2007:17315. doi: 10.1155/2007/17315.

11.

A cord of three strands--medical synchronization meetings improve the delivery of health care in combat.

Wilson RL, Hoekman KB, Natvig GE.

Mil Med. 2008 Jan;173(1):vii-viii. No abstract available.

PMID:
18251324
12.

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.

van der Veldt AA, van den Eertwegh AJ, Hoekman K, Barkhof F, Boven E.

Ann Oncol. 2007 Oct;18(10):1747-50. No abstract available.

PMID:
17890217
13.

VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients.

Vroling L, Yuana Y, Schuurhuis GJ, van Hinsbergh VW, Gundy C, de Haas R, van Cruijsen H, Boven E, Hoekman K, Broxterman HJ.

Thromb Haemost. 2007 Aug;98(2):440-50.

PMID:
17721629
14.

Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS.

Jimenez CR, El Filali Z, Knol JC, Hoekman K, Kruyt FA, Giaccone G, Smit AB, Li KW.

Proteomics Clin Appl. 2007 Jun;1(6):598-604. doi: 10.1002/prca.200600483. Epub 2007 May 11.

PMID:
21136711
15.

Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.

van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh VW, Löwik CW.

Eur J Cancer. 2007 Jan;43(2):433-42. Epub 2006 Nov 9.

PMID:
17097285
16.

The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

Meijerink MR, van Cruijsen H, Hoekman K, Kater M, van Schaik C, van Waesberghe JH, Giaccone G, Manoliu RA.

Eur Radiol. 2007 Jul;17(7):1700-13. Epub 2006 Oct 27.

PMID:
17072618
17.
18.

Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis.

van Heijst JW, Niessen HW, Musters RJ, van Hinsbergh VW, Hoekman K, Schalkwijk CG.

Cancer Lett. 2006 Sep 28;241(2):309-19. Epub 2005 Dec 6.

PMID:
16337338
19.

Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies.

van Cruijsen H, Giaccone G, Hoekman K.

Int J Cancer. 2005 Dec 20;117(6):883-8. Review.

20.

Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.

Kuenen BC, Giaccone G, Ruijter R, Kok A, Schalkwijk C, Hoekman K, Pinedo HM.

Clin Cancer Res. 2005 Sep 1;11(17):6240-6.

21.

Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine.

van Heijst JW, Niessen HW, Hoekman K, Schalkwijk CG.

Ann N Y Acad Sci. 2005 Jun;1043:725-33.

PMID:
16037299
22.

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.

Hansma AH, Broxterman HJ, van der Horst I, Yuana Y, Boven E, Giaccone G, Pinedo HM, Hoekman K.

Ann Oncol. 2005 Oct;16(10):1695-701. Epub 2005 Jul 12.

PMID:
16012180
23.

The hemostatic system in angiogenesis.

van Hinsbergh VW, Koolwijk P, Hoekman K.

EXS. 2005;(94):247-66. Review. No abstract available.

PMID:
15617483
24.

Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate.

de Bruin M, van Capel T, Smid K, van der Born K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1485-90.

PMID:
15571282
25.

Systemic and peritoneal angiogenic response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial.

Wu FP, Hoekman K, Sietses C, von Blomberg BM, Meijer S, Bonjer HJ, Cuesta MA.

Dis Colon Rectum. 2004 Oct;47(10):1670-4.

PMID:
15540297
26.

Angiogenesis: a potential target for therapy of soft tissue sarcomas.

Hoekman K, Pinedo HM.

Cancer Treat Res. 2004;120:169-80. Review. No abstract available.

PMID:
15217224
27.

Clarifying the term 'palliative' in clinical oncology.

van Kleffens T, Van Baarsen B, Hoekman K, Van Leeuwen E.

Eur J Cancer Care (Engl). 2004 Jul;13(3):263-71.

PMID:
15196230
28.

VEGF and endostatin levels in wound fluid and plasma after breast surgery.

Wu FP, Hoekman K, Meijer S, Cuesta MA.

Angiogenesis. 2003;6(4):255-7.

PMID:
15166493
29.

The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.

De Bruin M, Van Capel T, Smid K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Eur J Pharmacol. 2004 May 3;491(2-3):93-9.

PMID:
15140625
30.

A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour.

Hansma AH, van Hensbergen Y, Kuenen BC, van Diest PJ, Hanemaaijer R, Meijer S, Pinedo HM, Hoekman K.

J Clin Pathol. 2004 May;57(5):536-8.

31.

Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts.

van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MC, Hoekman K, Pinedo HM, Boven E.

Clin Cancer Res. 2004 Feb 1;10(3):1180-91.

32.

The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma.

Wu FP, Westphal JR, Hoekman K, Mels AK, Statius Muller MG, de Waal RW, Beelen RH, van Leeuwen PA, Meijer S, Cuesta MA.

Cytokine. 2004 Jan 21;25(2):68-72.

PMID:
14693162
33.

Effects of major liver resection, with or without recombinant bactericidal/permeability-increasing protein (rBPI21), on the angiogenic profile of patients with metastatic colorectal carcinoma.

Wu FP, Boelens PG, van Leeuwen PA, Hoekman K, Hansma AH, Wiezer MJ, Meijer C, Meijer S, Scotté M, Cuesta MA.

J Surg Oncol. 2003 Nov;84(3):137-42.

PMID:
14598357
34.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

Twelves C, Hoekman K, Bowman A, Vermorken JB, Anthoney A, Smyth J, van Kesteren C, Beijnen JH, Uiters J, Wanders J, Gomez J, Guzmán C, Jimeno J, Hanauske A.

Eur J Cancer. 2003 Sep;39(13):1842-51.

PMID:
12932661
35.

Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Verstappen CC, Heimans JJ, Hoekman K, Postma TJ.

Drugs. 2003;63(15):1549-63. Review.

PMID:
12887262
36.

Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.

Broxterman HJ, Lankelma J, Hoekman K.

Drug Resist Updat. 2003 Jun;6(3):111-27. Review.

PMID:
12860459
37.

Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.

Verstappen CC, Postma TJ, Hoekman K, Heimans JJ.

J Neurooncol. 2003 Jun;63(2):201-5.

PMID:
12825825
38.

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM.

J Clin Oncol. 2003 Jun 1;21(11):2192-8.

PMID:
12775746
39.

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL.

Clin Cancer Res. 2003 May;9(5):1648-55.

40.

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

de Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Br J Cancer. 2003 Mar 24;88(6):957-64.

41.

Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells.

de Bruin M, Smid K, Laan AC, Noordhuis P, Fukushima M, Hoekman K, Pinedo HM, Peters GJ.

Biochem Biophys Res Commun. 2003 Feb 14;301(3):675-9.

PMID:
12565833
42.

Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.

van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K.

Clin Cancer Res. 2002 Dec;8(12):3747-54.

43.

Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia.

van Doorn J, Hoogerbrugge CM, Koster JG, Bloemen RJ, Hoekman K, Mudde AH, van Buul-Offers SC.

Clin Chem. 2002 Oct;48(10):1739-50.

44.

Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients.

Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K.

Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1500-5.

45.

Treatment of haemangiopericytoma-associated hypoglycaemia with embolisation.

Nanayakkara PW, van Doorn J, van den Berg FG, van Groeningen CJ, Pinedo HM, Hoekman K.

Eur J Intern Med. 2002 Aug;13(5):340-343.

PMID:
12144915
46.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH.

Anticancer Drugs. 2002 Apr;13(4):381-93.

PMID:
11984084
47.

A doxorubicin-CNGRC-peptide conjugate with prodrug properties.

van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K, Pinedo HM.

Biochem Pharmacol. 2002 Mar 1;63(5):897-908.

PMID:
11911842
48.

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

Kuenen BC, Rosen L, Smit EF, Parson MR, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJ, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G.

J Clin Oncol. 2002 Mar 15;20(6):1657-67.

PMID:
11896117
49.

Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor.

Peters GJ, De Bruin M, Fukushima M, Van Triest B, Hoekman K, Pinedo HM, Ackland SP.

Adv Exp Med Biol. 2000;486:291-4. Review. No abstract available.

PMID:
11783503
50.

SU6668, a multitargeted angiogenesis inhibitor.

Hoekman K.

Cancer J. 2001 Nov-Dec;7 Suppl 3:S134-8. Review.

PMID:
11779084

Supplemental Content

Loading ...
Support Center